Tissue Factor – Coagulation Factor VIIa complex (TF-FVIIa)

The Tissue Factor – Coagulation Factor VIIa (TF-FVIIa) complex, also known as the extrinsic tenase, is the primary physiological initiator of the blood coagulation cascade [3, 10]. It is formed when Tissue Factor (TF), a transmembrane protein expressed on extravascular cells, is exposed to circulating Factor VIIa (FVIIa) following vascular injury [7, 10]. Once assembled, the complex proteolytically activates Factors IX and X, which are critical steps in the generation of thrombin and the subsequent formation of a fibrin clot [3, 7]. Beyond its central role in hemostasis, the TF-FVIIa complex acts as a signaling scaffold that activates Protease-Activated Receptor 2 (PAR2), thereby modulating cellular processes such as inflammation, angiogenesis, and tumor metastasis [1, 5, 13]. In pathological states, aberrant expression of TF on monocytes or tumor cells can lead to life-threatening thrombosis or promote cancer progression [1, 16]. Consequently, the TF-FVIIa complex is a major therapeutic target for the development of novel anticoagulants and anti-tumor agents, though the primary challenge remains achieving efficacy without inducing excessive bleeding [2, 4, 8].

Other names

Extrinsic Tenase complexTF-FVIIa complexFactor III-Factor VIIa complexThromboplastin-Factor VIIa complex

The Tissue Factor – Coagulation Factor VIIa complex initiates the extrinsic pathway of coagulation by proteolytically activating Factors IX and X. Drugs targeting this complex function by either blocking the active site of Factor VIIa, preventing the assembly of the complex by binding to Tissue Factor, or allosterically inhibiting the complex's enzymatic activity, thereby reducing thrombin generation and fibrin formation.